Your Health. Your Family. Your Choice.
Administered by: Work Purchased by: ?
Life Threatening? No
Write-up: COVID-19 Infection; COVID-19 Infection; This is a spontaneous report received from a contactable other hcp. A 46-years-old non-pregnant female patient received bnt162b2 (COMIRNATY, formulation: solution for injection, Batch/Lot Number: EL3248), via an unspecified route of administration, administered in arm left on an unspecified date (age at vaccination 45 years) as DOSE 2, SINGLE for covid-19 immunization. Medical history included high blood pressure, high cholesterol, and osteoarthritis from an unknown date and unknown if ongoing. The patient''s known allergies were none. The patient was not tested for covid prior to vaccination but was tested positive after vaccination. The patient did not take any other vaccine in four weeks. The patient''s historical vaccine included BNT162B2 (1st dose was taken by patient via intramuscular in left arm on 03Mar2021,11:15 am, lot number: EN6203, age 45 years). Concomitant medications included atorvastatin (LIPITOR), amlodipine besilate (NORVASC) and celecoxib (CELEBREX) taken for an unspecified indication, start and stop date were not reported. The patient experienced covid-19 infection (drug ineffective) and covid-19 positive on 08Jul2021. The patient underwent lab tests and procedures which included sars-cov-2 test: positive on 11Jul2021 Nasal Swab (rapid). The patient did not take the treatment for events. The patient was not admitted to hospital, awareness date was reported to be 11Jul2021 and device stamp date was 13Jul2021. The outcome of the events was not resolved.; Sender''s Comments: Based on the known safety profile of the drug, a causal association between the reported events of drug ineffective, covid-19 and suspect drug bnt162b2 cannot be excluded.
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166